A citation-based method for searching scientific literature

Lucia Brilli, Cristina Dalmiglio, Tania Pilli, Filomena Barbato, Fabio Maino, Marco Capezzone, Alessandra Cartocci, Maria Grazia Castagna. J Clin Med 2021
Times Cited: 2







List of co-cited articles
7 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Lenvatinib and Subsequent Therapy for Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Real-World Study of Clinical Effectiveness in the United States.
Jonathan K Kish, Debanjana Chatterjee, Yin Wan, Hsing-Ting Yu, Djibril Liassou, Bruce A Feinberg. Adv Ther 2020
17
100

Radioactive iodine-refractory differentiated thyroid cancer: an uncommon but challenging situation.
Angelica Schmidt, Laura Iglesias, Michele Klain, Fabián Pitoia, Martin J Schlumberger. Arch Endocrinol Metab 2017
41
100

Lenvatinib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Candidate Biomarkers Associated with Survival: A Multicenter Study in Korea.
Eyun Song, Mijin Kim, Eui Young Kim, Bo Hyun Kim, Dong Yeob Shin, Ho-Cheol Kang, Byeong-Cheol Ahn, Won Bae Kim, Young Kee Shong, Min Ji Jeon,[...]. Thyroid 2020
20
100

Lenvatinib as first-line treatment for advanced thyroid cancer: long progression-free survival.
Simone De Leo, Marta Di Stefano, Luca Persani, Laura Fugazzola, Carla Colombo. Endocrine 2021
13
100

2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.
Bryan R Haugen, Erik K Alexander, Keith C Bible, Gerard M Doherty, Susan J Mandel, Yuri E Nikiforov, Furio Pacini, Gregory W Randolph, Anna M Sawka, Martin Schlumberger,[...]. Thyroid 2016
100

Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.
Martin Schlumberger, Makoto Tahara, Lori J Wirth, Bruce Robinson, Marcia S Brose, Rossella Elisei, Mouhammed Amir Habra, Kate Newbold, Manisha H Shah, Ana O Hoff,[...]. N Engl J Med 2015
974
100

Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.
Marcia S Brose, Christopher M Nutting, Barbara Jarzab, Rossella Elisei, Salvatore Siena, Lars Bastholt, Christelle de la Fouchardiere, Furio Pacini, Ralf Paschke, Young Kee Shong,[...]. Lancet 2014
858
100

Rapid response to sorafenib in metastatic medullary thyroid carcinoma.
K Frank-Raue, M Ganten, M C Kreissl, F Raue. Exp Clin Endocrinol Diabetes 2011
14
50

Efficacy of Selpercatinib in RET-Altered Thyroid Cancers.
Lori J Wirth, Eric Sherman, Bruce Robinson, Benjamin Solomon, Hyunseok Kang, Jochen Lorch, Francis Worden, Marcia Brose, Jyoti Patel, Sophie Leboulleux,[...]. N Engl J Med 2020
192
50

Cabozantinib in progressive medullary thyroid cancer.
Rossella Elisei, Martin J Schlumberger, Stefan P Müller, Patrick Schöffski, Marcia S Brose, Manisha H Shah, Lisa Licitra, Barbara Jarzab, Viktor Medvedev, Michael C Kreissl,[...]. J Clin Oncol 2013
673
50

A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer.
Shunji Takahashi, Naomi Kiyota, Tomoko Yamazaki, Naoko Chayahara, Kenji Nakano, Lina Inagaki, Kazuhisa Toda, Tomohiro Enokida, Hironobu Minami, Yoshinori Imamura,[...]. Future Oncol 2019
73
50

Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life.
Smita S Joshi, Sara Ortiz, Joslyn N Witherspoon, Alfred Rademaker, Dennis P West, Roger Anderson, Sara E Rosenbaum, Mario E Lacouture. Cancer 2010
123
50


Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.
Vivek Subbiah, Robert J Kreitman, Zev A Wainberg, Jae Yong Cho, Jan H M Schellens, Jean Charles Soria, Patrick Y Wen, Christoph Zielinski, Maria E Cabanillas, Gladys Urbanowitz,[...]. J Clin Oncol 2018
371
50

Defining Radioiodine-Refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT Trial.
Naomi Kiyota, Bruce Robinson, Manisha Shah, Ana O Hoff, Matthew H Taylor, Di Li, Corina E Dutcus, Eun Kyung Lee, Sung-Bae Kim, Makoto Tahara. Thyroid 2017
26
50


Lenvatinib in Advanced Radioiodine-refractory Thyroid Cancer: A Snapshot of Real-life Clinical Practice.
Alice Nervo, Marco Gallo, Maria Teresa Samà, Francesco Felicetti, Martina Alfano, Enrica Migliore, Filippo Marchisio, Rita Berardelli, Emanuela Arvat, Alessandro Piovesan. Anticancer Res 2018
28
50

Lenvatinib: Role in thyroid cancer and other solid tumors.
Maria E Cabanillas, Mouhammed Amir Habra. Cancer Treat Rev 2016
100
50

Lenvatinib for Anaplastic Thyroid Cancer and Lenvatinib-Induced Thyroid Dysfunction.
Satoshi Koyama, Naritomo Miyake, Kazunori Fujiwara, Tsuyoshi Morisaki, Takahiro Fukuhara, Hiroya Kitano, Hiromi Takeuchi. Eur Thyroid J 2018
18
50

Real-life use of lenvatinib in patients with differentiated thyroid cancer: experience from Argentina.
Fernando Jerkovich, Inés Califano, Fernanda Bueno, Juan Manuel Carrera, Raúl Giglio, Erika Abelleira, Fabián Pitoia. Endocrine 2020
14
50

Updated comprehensive epidemiology, microbiology, and outcomes among patients with acute cholangitis.
Harumi Gomi, Tadahiro Takada, Tsann-Long Hwang, Kohei Akazawa, Rintaro Mori, Itaru Endo, Fumihiko Miura, Seiki Kiriyama, Naohisa Matsunaga, Takao Itoi,[...]. J Hepatobiliary Pancreat Sci 2017
36
50

Activity of the Highly Specific RET Inhibitor Selpercatinib (LOXO-292) in Pediatric Patients With Tumors Harboring RET Gene Alterations.
Michael V Ortiz, Ulrike Gerdemann, Sandya Govinda Raju, Dahlia Henry, Steve Smith, S Michael Rothenberg, Michael C Cox, Stéphanie Proust, Julia Glade Bender, A Lindsay Frazier,[...]. JCO Precis Oncol 2020
18
50

Relationship between adverse events associated with lenvatinib treatment for thyroid cancer and patient prognosis.
Hiroyuki Iwasaki, Soji Toda, Daisuke Murayama, Shin Kato, Ai Matsui. Mol Clin Oncol 2021
5
50

Real-World Experience with Targeted Therapy for the Treatment of Anaplastic Thyroid Carcinoma.
Priyanka C Iyer, Ramona Dadu, Renata Ferrarotto, Naifa L Busaidy, Mouhammed A Habra, Mark Zafereo, Neil Gross, Kenneth R Hess, Maria Gule-Monroe, Michelle D Williams,[...]. Thyroid 2018
53
50

Management of advanced medullary thyroid cancer.
Julien Hadoux, Furio Pacini, R Michael Tuttle, Martin Schlumberger. Lancet Diabetes Endocrinol 2016
62
50

Real-World Treatment Patterns Among Patients Initiating Small Molecule Kinase Inhibitor Therapies for Thyroid Cancer in the United States.
Stacey A Dacosta Byfield, Oluwakayode Adejoro, Ronda Copher, Debanjana Chatterjee, Prashant R Joshi, Francis P Worden. Adv Ther 2019
9
50


Vandetanib: in medullary thyroid cancer.
James E Frampton. Drugs 2012
20
50

Biologic and Clinical Perspectives on Thyroid Cancer.
James A Fagin, Samuel A Wells. N Engl J Med 2016
421
50

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.
Georgia Hatzivassiliou, Kyung Song, Ivana Yen, Barbara J Brandhuber, Daniel J Anderson, Ryan Alvarado, Mary J C Ludlam, David Stokoe, Susan L Gloor, Guy Vigers,[...]. Nature 2010
50

Clinical Pharmacokinetics and Pharmacodynamics of Dabrafenib.
Alicja Puszkiel, Gaëlle Noé, Audrey Bellesoeur, Nora Kramkimel, Marie-Noëlle Paludetto, Audrey Thomas-Schoemann, Michel Vidal, François Goldwasser, Etienne Chatelut, Benoit Blanchet. Clin Pharmacokinet 2019
40
50

Neoadjuvant selpercatinib for advanced medullary thyroid cancer.
Yelda Jozaghi, Mark Zafereo, Michelle D Williams, Maria K Gule-Monroe, Jennifer Wang, Elizabeth G Grubbs, Ara Vaporciyan, Mimi I Hu, Naifa Busaidy, Ramona Dadu,[...]. Head Neck 2021
19
50

Lenvatinib: A Promising Molecular Targeted Agent for Multiple Cancers.
Koichi Suyama, Hirotaka Iwase. Cancer Control 2018
47
50

Inhibition of the AKT/mTOR Pathway Augments the Anticancer Effects of Sorafenib in Thyroid Cancer.
Heqing Yi, Xuemei Ye, Bin Long, Ting Ye, Lijun Zhang, Fengqin Yan, Yang Yang, Linfa Li. Cancer Biother Radiopharm 2017
17
50

Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.
Samuel A Wells, Bruce G Robinson, Robert F Gagel, Henning Dralle, James A Fagin, Massimo Santoro, Eric Baudin, Rossella Elisei, Barbara Jarzab, James R Vasselli,[...]. J Clin Oncol 2012
865
50

Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma.
M Schlumberger, R Elisei, S Müller, P Schöffski, M Brose, M Shah, L Licitra, J Krajewska, M C Kreissl, B Niederle,[...]. Ann Oncol 2017
90
50

Sorafenib for the Treatment of Progressive Metastatic Medullary Thyroid Cancer: Efficacy and Safety Analysis.
Luciana Audi de Castroneves, Marcelo Vailati Negrão, Ricardo Miguel Costa de Freitas, Carla Papadia, José Viana Lima, Julia T Fukushima, Eduardo Furquim Simão, Marco Aurélio Vamondes Kulcsar, Marcos Roberto Tavares, Alexander Augusto de Lima Jorge,[...]. Thyroid 2016
27
50

Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in BRAFV600E-Mutated Anaplastic Thyroid Carcinoma.
Jennifer R Wang, Mark E Zafereo, Ramona Dadu, Renata Ferrarotto, Naifa L Busaidy, Charles Lu, Salmaan Ahmed, Maria K Gule-Monroe, Michelle D Williams, Erich M Sturgis,[...]. Thyroid 2019
80
50

Trametinib (GSK1120212).
Robert Zeiser, Hana Andrlová, Frank Meiss. Recent Results Cancer Res 2018
17
50

Tokyo Guidelines 2018: antimicrobial therapy for acute cholangitis and cholecystitis.
Harumi Gomi, Joseph S Solomkin, David Schlossberg, Kohji Okamoto, Tadahiro Takada, Steven M Strasberg, Tomohiko Ukai, Itaru Endo, Yukio Iwashita, Taizo Hibi,[...]. J Hepatobiliary Pancreat Sci 2018
130
50

Efficacy and Limitations of Lenvatinib Therapy for Radioiodine-Refractory Differentiated Thyroid Cancer: Real-World Experiences.
Chie Masaki, Kiminori Sugino, Naoko Saito, Junko Akaishi, Kiyomi Y Hames, Chisato Tomoda, Akifumi Suzuki, Kenichi Matsuzu, Takashi Uruno, Keiko Ohkuwa,[...]. Thyroid 2020
26
50

NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018.
Robert I Haddad, Christian Nasr, Lindsay Bischoff, Naifa Lamki Busaidy, David Byrd, Glenda Callender, Paxton Dickson, Quan-Yang Duh, Hormoz Ehya, Whitney Goldner,[...]. J Natl Compr Canc Netw 2018
139
50

Lenvatinib for Anaplastic Thyroid Cancer.
Makoto Tahara, Naomi Kiyota, Tomoko Yamazaki, Naoko Chayahara, Kenji Nakano, Lina Inagaki, Kazuhisa Toda, Tomohiro Enokida, Hironobu Minami, Yoshinori Imamura,[...]. Front Oncol 2017
90
50

Safety of Tyrosine Kinase Inhibitors in Patients With Differentiated Thyroid Cancer: Real-World Use of Lenvatinib and Sorafenib in Korea.
Soo Young Kim, Seok-Mo Kim, Hojin Chang, Bup-Woo Kim, Yong Sang Lee, Hang-Seok Chang, Cheong Soo Park. Front Endocrinol (Lausanne) 2019
15
50

Natural history, diagnosis, treatment and outcome of medullary thyroid cancer: 37 years experience on 157 patients.
M R Pelizzo, I M Boschin, P Bernante, A Toniato, A Piotto, C Pagetta, O Nibale, L Rampin, P C Muzzio, D Rubello. Eur J Surg Oncol 2007
133
50

Symptomatic Biliary Disorders During Lenvatinib Treatment for Thyroid Cancer: An Underestimated Problem.
Alice Nervo, Alberto Ragni, Marco Gallo, Andrea Ferraris, Paolo Fonio, Alessandro Piovesan, Emanuela Arvat. Thyroid 2020
7
50

Radioiodine refractory differentiated thyroid cancer.
Yuchen Jin, Douglas Van Nostrand, Lingxiao Cheng, Min Liu, Libo Chen. Crit Rev Oncol Hematol 2018
42
50

Extended Real-World Observation of Patients Treated with Sorafenib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Impact of Lenvatinib Salvage Treatment: A Korean Multicenter Study.
Hye-Seon Oh, Dong Yeob Shin, Mijin Kim, So Young Park, Tae Hyuk Kim, Bo Hyun Kim, Eui Young Kim, Won Bae Kim, Jae Hoon Chung, Young Kee Shong,[...]. Thyroid 2019
12
50

2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer.
Keith C Bible, Electron Kebebew, James Brierley, Juan P Brito, Maria E Cabanillas, Thomas J Clark, Antonio Di Cristofano, Robert Foote, Thomas Giordano, Jan Kasperbauer,[...]. Thyroid 2021
72
50

Management of Medullary Thyroid Cancer.
David Viola, Rossella Elisei. Endocrinol Metab Clin North Am 2019
30
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.